Bengaluru's LiteFold builds an AI co-scientist platform to speed up drug discovery for biotechnologists. This addresses a significant bottleneck: computational biologists often spend more time building software tools than solving biological problems. Its Rosalind platform lets researchers run hundreds of hypotheses in parallel, potentially cutting years off therapeutic design.
How We Got Here
Founded in 2025 by ML engineer Anindyadeep Sannigrahi, LiteFold emerged from his AI residency at Bengaluru's Lossfunk. Sannigrahi's pivot to biotech followed the 2024 Nobel Prize recognizing computational protein design, highlighting the sector's tooling gap.
The Numbers
- Sannigrahi connected with American computational biologist Cory Kornowicz on X, who then joined LiteFold as co-founder.
- The five-member startup operates from Bengaluru and Delaware in the US, indicating a hybrid global presence.
- LiteFold's "Rosalind" AI co-scientist integrates workflows from AI research to legal processes, though it excludes the wet lab stage.
- The platform significantly increases "educated guesses" by running multiple hypotheses simultaneously, a bottleneck in traditional R&D.
- The founders envision expanding beyond therapeutic design into broader biological engineering in the future.
What Happens Next
🇮🇳 Why This Matters for India
For the biotech R&D hubs in Hyderabad, Pune, and Ahmedabad, LiteFold offers a direct path to accelerate early-stage drug validation, compressing expensive development cycles.
The Take
LiteFold aims for an "IDE for computational biologists," but the challenge remains true end-to-end integration. The current exclusion of the wet lab means they are automating a segment, not replacing the entire drug discovery pipeline.
Source:
YourStory ↗